X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://www.globenewswire.com//news-release/2023/12/11/2794238/0/en/Nature-Medicine-Study-Validates-PredicineBEACON-MRD-Liquid-Biopsy-Assay-in-Genentech-s-Phase-1b-Clinical-Trial-of-Divarasib-Plus-Cetuximab-in-CRC.html
https://www.expresspharma.in/enzene-biosciences-launches-cetuximab-biosimilar-of-cancer-drug-erbitux/
https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/lupin-launches-biosimilar-cetuximab-in-pact-with-enzene/articleshow/100628282.cms
https://www.globenewswire.com/news-release/2023/04/18/2649068/0/en/SOLVE-FSHD-invests-in-Epic-Bio-for-the-development-of-a-novel-treatment-for-Facioscapulohumeral-Muscular-Dystrophy.html
https://www.prnewswire.com/news-releases/genfleet-receives-ema-approval-for-phase-ibii-study-of-gfh925-kras-g12c-inhibitor-in-combination-with-erbitux-cetuximab-treating-patients-with-advanced-nsclc-in-first-line-setting-301759066.html
https://www.prnewswire.com/news-releases/genfleet-therapeutics-and-merck-enter-into-trial-collaboration-to-initiate-study-investigating-combination-therapy-of-gfh925-kras-g12c-inhibitor-and-erbitux-cetuximab-301704921.html
https://www.prnewswire.com/news-releases/jacobio-pharma-to-collaborate-with-merck-on-clinical-trial-of-jab-21822-in-combination-with-cetuximab-301647596.html
https://www.prnewswire.com/news-releases/jacobio-receives-cde-approval-for-kras-g12c-inhibitor-jab-218822s-phase-ii-pivotal-study-in-china-301618023.html
https://www.clinicaltrialsarena.com/news/alx-colorectal-cancer-trial/
https://www.globenewswire.com/news-release/2022/08/11/2496561/0/en/ALX-Oncology-Announces-First-Patient-Dosed-in-Phase-2-Investigator-Sponsored-Trial-of-Evorpacept-in-Combination-with-Cetuximab-and-Pembrolizumab-in-Patients-with-Advanced-Colorecta.html
https://www.clinicaltrialsarena.com/news/erasca-eli-lilly-therapy-colorectal-cancer/
https://www.globenewswire.com/news-release/2022/06/22/2467067/0/en/AVEO-Oncology-Announces-Clinical-Trial-Collaboration-and-Supply-Agreement-with-Eli-Lilly-and-Company-for-ERBITUX-cetuximab-in-North-America-to-Evaluate-Ficlatuzumab-and-Cetuximab-i.html
https://www.prnewswire.com/news-releases/biond-biologics-announces-first-patients-dosed-with-bnd-22-sar444881-combinations-in-phase-1-clinical-trial-301552737.html
https://www.globenewswire.com/news-release/2022/03/10/2400830/0/en/Erasca-Announces-Clinical-Trial-Collaboration-and-Supply-Agreement-with-Eli-Lilly-and-Company-to-Evaluate-ERAS-007-and-Cetuximab-Combination.html
https://www.prnewswire.com/news-releases/jacobio-jab-21822-in-combination-with-cetuximab-completes-first-dose-of-colorectal-cancer-patient-in-china-301489230.html
https://www.prnewswire.com/news-releases/jacobio-receives-ind-approval-for-combination-therapy-of-kras-g12c-and-cetuximab-injection-in-china-301437611.html
https://www.asiaone.com/business/jacobio-receives-ind-approval-combination-therapy-kras-g12c-and-cetuximab-injection-china
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214864
https://www.businesswire.com/news/home/20211024005038/en/NANOBIOTIX-Announces-18.1-Month-Median-Overall-Survival-for-41-Evaluable-Elderly-and-Frail-Patients-With-HNSCC-in-Phase-I-Expansion-Evaluating-Nbtxr3-as-a-Single-Agent-Activated-by-Radiotherapy
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084
https://www.cancernetwork.com/view/promising-preliminary-data-for-kras-g12c-inhibition-with-adagrasib-is-presented-for-crc
https://www.prnewswire.com/news-releases/mirati-therapeutics-presents-positive-clinical-data-with-investigational-adagrasib-as-monotherapy-and-in-combination-with-cetuximab-in-patients-with-kras-g12c-mutated-colorectal-cancer-301379950.html
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-new-dosing-regimen-cetuximab
http://www.pharmatimes.com/news/nice_backs_braftovi_for_braf-positive_colorectal_cancer_1357546
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084
https://pipelinereview.com/index.php/2020070375207/Small-Molecules/Menarini-Ricerche-Announces-C-PRECISE-01-a-New-Phase-Ib/II-Trial-of-MEN1611-in-Colorectal-Cancer.html
https://www.globenewswire.com/news-release/2020/06/01/2041617/0/en/Junshi-Biosciences-and-Merck-Announce-Collaboration-to-Explore-Promising-New-COMBINATION-Treatment-for-Head-and-Neck-Cancer-Patients-in-China.html
https://www.globenewswire.com/news-release/2020/05/22/2037517/0/en/Kitov-Announces-U-S-FDA-Acceptance-of-Investigational-New-Drug-Application-to-Conduct-Phase-1-2-Clinical-Trial-of-NT219-in-Multiple-Types-of-Advanced-Cancer-Patients.html
https://www.globenewswire.com/news-release/2020/05/14/2033189/0/en/Innate-Pharma-to-Present-New-Efficacy-Data-For-Monalizumab-in-Combination-With-Cetuximab-in-Head-And-Neck-cancer-at-The-ASCO20-Virtual-Scientific-Progral.html
http://www.pharmatimes.com/news/ema_validates_bratovi,_mektovi_application_for_some_mcrc_1315939
https://www.biospace.com/article/releases/merck-receives-positive-eu-chmp-opinion-for-two-new-regimens-of-keytruda-pembrolizumab-as-first-line-treatment-for-metastatic-or-unresectable-recurrent-head-and-neck-squamous-cell-carcinoma-/?s=95
http://www.pmlive.com/pharma_news/innate_pharma_and_astrazeneca_take_monalizumab_into_phase_3_1302699
https://www.fiercepharma.com/pharma/roche-merck-novartis-and-others-raise-prices-83-meds-to-start-july-analyst?utm_source=internal&utm_medium=rss
http://www.pharmafile.com/news/524241/pierre-fabres-triplet-therapy-makes-strong-showing-braf-v600e-mutant-metastatic-colorect
https://www.biospace.com/article/array-biopharma-s-triple-drug-combo-could-be-gamechanger-for-colorectal-cancer/
https://www.businesswire.com/news/home/20190706005001/en/Pierre-Fabre-partner-Array-BioPharma-announce-interim
Market Place
Share 
